EU Approval Makes ESR1 Emergence Actionable
The European Commission approved AstraZeneca’s Etcamah, or camizestrant, with a CDK4/6 inhibitor for adults with ER-positive, HER2-negative advanced breast cancer when an ESR1 mutation emerges during first-line aromatase-inhibitor plus CDK4/6 therapy but before disease…
